ZUG, Switzerland, January 11, 2016 /PRNewswire/ --

LifeWatch AG (SIX Swiss Exchange: LIFE), a leading developer and provider of medical solutions and remote diagnostic monitoring services to the digital health market, is pleased to announce the signing of an agreement with AliveCor Inc. to utilize the AliveCor (R) Mobile ECG technology in its cardiac monitoring business. We are working together to integrate the AliveCor Mobile ECG into LifeWatch's cardiac monitoring product offering.

Dr. Stephan Rietiker, CEO of LifeWatch, commented, "Digital health monitoring is revolutionizing how people interact with healthcare delivery. The AliveCor Mobile ECG will enable LifeWatch to broaden its cardiac event monitoring services, whilst at the same time opening the door to post-event cardiac monitoring via a patient's own mobile device. This will provide the patient with greater control and convenience. At the same time, physicians will benefit from a broader range of attractive, diagnostic options. AliveCor's technology offering complements that of LifeWatch, and emphasizes our commitment to using the most innovative technologies available."

"We are excited about expanding into the remote patient monitoring market, which will allow us to have a bigger impact on people's lives and bring healthcare into the 21st century," said Vic Gundotra, chief executive officer of AliveCor. "Using the AliveCor Mobile ECG will keep patients in touch with their physicians outside of the hospital and can help to identify cardiac problems before something life-threatening occurs."

The AliveCor Mobile ECG records accurate ECGs and heart rate anywhere and at any time. The customer simply rests the fingers on the device or places the device to the chest to record an ECG in just 30 seconds. A first response is provided immediately with an in-depth expert analysis available as required.

About LifeWatch AG: 

LifeWatch AG, headquartered in Zug and listed on SIX Swiss Exchange (LIFE), Switzerland, is a leading healthcare technology and solution company, specializing in advanced digital health systems and wireless remote diagnostic patient monitoring services. LifeWatch's services provide physicians with critical information to determine appropriate treatment and thereby improve patient outcomes. LifeWatch AG has operative subsidiaries in the United States, in Switzerland and in Israel, and is the parent company of LifeWatch Services Inc., and LifeWatch Technologies, Ltd. LifeWatch Services, Inc. is a leading U.S.-based provider of cardiac monitoring services and home sleep testing of Obstructive Sleep Apnea (OSA). LifeWatch Technologies Ltd., based in Israel, is a leading developer and manufacturer of telemedicine products. For additional information, please visit http://www.lifewatch.com.

About AliveCor, Inc. 

AliveCor Inc., is recognized around the world for transforming cardiac care. The FDA cleared AliveCor(R) Mobile ECG is the most clinically validated mobile ECG monitor on the market. It is recommended by leading cardiologists and used by people worldwide for accurate ECG recordings. Today, we offer a simple to use mobile device and service providing instant analysis for detecting atrial fibrillation (AFib) and normal ECG's. AliveCor is a privately-held company headquartered in San Francisco, Calif. For more information, please visit http://www.alivecor.com.

AliveCor is a trademark of AliveCor, Inc., registered in the U.S. and other countries.

Sign up for customized e-mail alerts and documentation requests at http://www.irlifewatch.com/alert-service.aspx

This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding future results of operations and financial position, the business strategy, and plans and objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. LifeWatch AG has based these forward-looking statements largely on current expectations and projections about future events and financial trends that it believes may affect the financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. All forward-looking statements are based only on data available to LifeWatch AG at the time of the issue of this press release. LifeWatch AG does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES, OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT FROM REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE ISSUER. 


        
         
        For further questions: 
        LifeWatch AG 
        c/o Dynamics Group, Philippe Blangey / Doris Rudischhauser 
        Phone: +41-43-268-32-35 / +41-79-410-81-88 
        E-mail: investor-relations@lifewatch.com  

 

SOURCE LifeWatch AG